Cochlear sees no other suitors for Demant's implants business

The Australian would-be buyer has serious questions about ”whether any other company has the ability and the willingness” to shoulder the responsibility of Oticon Medical.
Photo: Cochlear / Pr
Photo: Cochlear / Pr
by mikkel aabenhus hemmingsen, translated by daniel pedersen

20,000 patients currently using an Oticon Medical implant stand to lose if competition authorities continue to block Demant’s divestment of the surgical unit to Australia-based Cochlear.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
  • Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
    Must contain at least 2 characters
    Must contain at least 2 characters

    Get full access for you and your coworkers

    Start a free company trial today

    Share article

    Sign up for our newsletter

    Stay ahead of development by receiving our newsletter on the latest sector knowledge.

    Newsletter terms

    Further reading